Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Buy Stock in Citigroup Inc. (C) Because of Corbat

Page 1 of 2

If you want to crack the code of a company — to really understand what makes it tick as a business and as an investment — one of the things you have to get your head around is who’s at the top: the person making the day-to-day and long-term decisions that will eventually make or break the company, and possibly your portfolio.

For Citigroup Inc. (NYSE:C), that person at the top is CEO Michael Corbat. Here’s the first of two articles taking an in-depth look at this relative newcomer to the superbank’s top spot: where he came from, some of the important decisions he’s made, and why you could arguably buy stock in the country’s third-largest bank solely because of his ascendancy to CEO.

Citigroup Inc (NYSE:C)

Citi’s made man
Corbat is a Citigroup Inc. (NYSE:C) lifer. He’s been with the bank for nearly 30 years and by all accounts is a “banker’s banker.” There’s nothing flashy or showy about him. He doesn’t have the big mouth and bluster of JPMorgan Chase & Co. (NYSE:JPM) CEO Jamie Dimon, nor the knowing smirk and achingly dry wit of Goldman Sachs Group, Inc. (NYSE:GS) CEO Lloyd Blankfein.

In lieu of these more-typical master-of-the-universe traits, and much to his credit, Corbat has a palpable sereneness and steadiness: forged in his long and storied service with Citigroup Inc. (NYSE:C). And based on some of the positions he’s held there, the man certainly must have some stories to tell.

His most high-profile position at Citigroup Inc. (NYSE:C) was his tenure as head of Citi Holdings: the “bad bank” spun off in the wake of the financial crisis to house the then-floundering superbank’s most poorly performing assets, along with the “non-core” lines of business Citigroup wanted to eventually get out of. The cleanup of Citi Holdings has been critical to the bank’s post-crash restructuring, and Corbat was there to be Citi’s shepherd in that particular valley of financial darkness.

Most recently, Corbat was head of Citigroup Inc. (NYSE:C)’s EMEA operations. EMEA is short for Europe, Middle East, and Africa. This is an axial post for Corbat to have held: In my opinion, in mature markets like North America and Europe growth almost inevitably has to come from overseas. In the first quarter of 2013, 53.1% of Citi’s total revenue was generated in EMEA: clearly making expertise in overseas operations highly valuable in a CEO.

JPMorgan Chase & Co. (NYSE:JPM) is Citi’s top big-banking competitor for global growth, with roughly 48.1% of its first-quarter revenue coming from overseas. At least Bank of America Corp (NYSE:BAC) isn’t as much in the running for global growth: only 18.1% of its first-quarter revenue came from overseas. Wells Fargo & Co (NYSE:WFC) isn’t even in the game, with only 3% of its first-quarter revenue generated overseas.

Foolish bottom line
One final note: Corbat’s ascension to CEO wasn’t a pretty one. In fact, it was particularly bloody, though you can’t blame it on Corbat.

Vikram Pandit was Citigroup Inc. (NYSE:C)’s previous CEO, and while it was clear that he and Chairman Michael E. O’Neill didn’t see eye-to-eye on everything, Pandit’s overall performance was solid. But Pandit’s October 2012 ouster by O’Neill was unusually swift and ruthless. Is this the fate that potentially awaits Corbat? This new, highly capable leader of Citigroup?

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!